Benzodiazepines are among the most prescribed medications in the United States, and for good reason: they work quickly, and anxiety is acutely distressing. The problem is not that benzodiazepines fail at their stated purpose. The problem is what happens after months or years of relying on a medication that manages symptoms without changing the neural patterns that produce them — and what the research shows about the risks that accumulate along the way. At Scottsdale Ketamine Clinic, we work with anxiety patients who have been through the standard pharmacological options and are asking whether there is a treatment that operates at a deeper level.
What Benzodiazepines Actually Do
Benzodiazepines — the drug class that includes medications like diazepam, lorazepam, and clonazepam — work by enhancing the activity of GABA, the brain’s primary inhibitory neurotransmitter. By amplifying GABA’s calming effect, benzodiazepines reduce neural activity broadly, which produces rapid relief from acute anxiety symptoms: the racing heart, the physical tension, the intrusive spiral of worry.
This mechanism is effective in the short term. It is also, over time, self-undermining. Long-term benzodiazepine use is associated with physical dependence, cognitive impairment including memory and processing difficulties, and a rebound phenomenon in which anxiety returns — often more intensely — when the medication is reduced or discontinued (National Center for Biotechnology Information). The brain adapts to the suppression of neural activity by downregulating its own GABA sensitivity, which means progressively higher doses are needed to produce the same effect, and withdrawal can trigger severe anxiety that far exceeds the original presentation.
None of this means benzodiazepines are never appropriate. For acute, short-term anxiety management, they remain a legitimate clinical tool. The concern arises when they become the long-term strategy — not because the prescribing clinician made a poor decision, but because the medication was designed for a different purpose than the one it ends up serving.
The Glutamate System and Anxiety’s Neural Architecture
Most anxiety pharmacology targets GABA, serotonin, or norepinephrine. These are meaningful pathways, and SSRIs and SNRIs help many anxiety patients significantly. But for patients with treatment-resistant anxiety — those who have completed adequate trials of first-line medications without sufficient relief — the neural architecture of their anxiety may involve systems that those medications do not directly address.
The glutamate system is the brain’s primary excitatory network. In anxiety disorders, glutamate dysregulation and overactive NMDA receptors contribute to the hyperexcitable neural states that sustain chronic worry, panic, and hypervigilance. This NMDA overactivity is not targeted by benzodiazepines, SSRIs, or SNRIs. It is, however, the primary target of ketamine for anxiety (National Center for Biotechnology Information).
Ketamine works by temporarily blocking NMDA receptors, which interrupts the overactive excitatory signaling that anxiety disorders involve. Beyond symptom suppression, ketamine promotes neuroplasticity — the brain’s capacity to form new neural connections and reorganize existing ones (National Center for Biotechnology Information). This neuroplastic effect is where the distinction between symptom management and neural change becomes most meaningful. Benzodiazepines reduce the experience of anxiety in the moment. Ketamine may alter the neural architecture that generates anxiety in the first place — not permanently or universally, but in ways that clinical evidence supports for a significant subset of patients who have not responded to conventional treatment (National Center for Biotechnology Information).
What the Research Shows
Clinical evidence for ketamine’s effectiveness in anxiety disorders has grown substantially over the past decade. Studies document rapid and significant reductions in anxiety symptoms following IV ketamine administration, with effects observed in patients whose anxiety had not responded to prior treatments (National Center for Biotechnology Information). The speed of response is one of the most clinically significant features: where SSRIs require weeks to produce their full effect, ketamine can reduce anxiety symptoms within hours of a single infusion.
This rapid onset is not simply a convenience. For patients with severe anxiety, the weeks of waiting for a medication to become effective are weeks of continued suffering — and in some cases, weeks of benzodiazepine use to manage the gap. Ketamine’s fast action does not make it universally superior to other treatments, but it represents a meaningfully different profile that matters for patients who have been waiting a long time for something to change.
The relationship between anxiety and depression is also clinically relevant here. Research confirms a strong bidirectional connection between the two conditions — anxiety and depression commonly co-occur, and each tends to worsen the other (American Journal of Psychiatry). Ketamine’s documented effectiveness across both conditions means that patients with the mixed presentations common in treatment-resistant mental health are not being asked to choose which diagnosis to address first.
Anxiety Treatment at Scottsdale Ketamine Clinic
We treat generalized anxiety disorder, social anxiety, and panic disorder with IV ketamine infusion therapy at both our Scottsdale and Phoenix locations. Every patient begins with a thorough intake evaluation conducted by our clinical team, led by Jenice Hughes, CRNA, a board-certified nurse anesthetist with more than four decades of clinical experience. We review your full history — prior medications, therapeutic approaches, current symptom burden, and treatment goals — before making any recommendation.
Infusions take place in private, comfortable treatment rooms with continuous clinical monitoring throughout each 45 to 60 minute session. The perceptual effects of ketamine — a mild sense of detachment, a quieting of the habitual anxious thought stream — are temporary and resolve after the session ends. Most patients find the infusion experience notably different from their expectations, particularly if anxiety about the infusion itself was part of what made them hesitate to schedule.
We are direct about what IV ketamine is not: it is not a cure, and it is not appropriate for every anxiety patient. Results vary by individual, and the goal of treatment is meaningful symptom reduction and improved function, not a promise of permanent resolution. For some patients, a foundational infusion series followed by maintenance sessions produces sustained relief. For others, ketamine is most useful as one component of a broader treatment approach that includes therapy, lifestyle modifications, or other pharmacological support. Discuss your options with your provider and let your clinical history guide the plan.
The Honest Conversation About Transitioning Away from Benzodiazepines
For patients currently using benzodiazepines and considering ketamine therapy, the question of how to manage that transition is one we take seriously. Benzodiazepine discontinuation requires a carefully supervised taper — abrupt cessation can trigger severe withdrawal including seizures, and this should never be attempted without medical oversight. We do not advise patients to discontinue benzodiazepines independently, and ketamine treatment does not accelerate or substitute for a medically supervised taper.
What ketamine may offer in this context is an alternative neurological support — addressing the glutamate dysregulation that benzodiazepines do not touch — while the clinical work of reducing benzodiazepine dependence proceeds on its own medically appropriate timeline. Whether this combination is right for your specific situation is a clinical determination, not a general recommendation. Raise it during your consultation and let your provider evaluate it in the context of your full history.
A Note on Cost
IV ketamine infusions for anxiety are off-label treatments and are not typically covered by insurance. We provide documentation to support out-of-network reimbursement requests, and our team discusses the financial details of treatment fully before any commitment is made. We do not treat the cost conversation as secondary — it is part of the information you need to make a real decision.
Frequently Asked Questions
Is ketamine safe to use if I am currently taking benzodiazepines? This depends on your specific medications, dosages, and clinical history. Many patients who take benzodiazepines have proceeded with ketamine therapy safely; others require modified protocols. This is assessed during the intake evaluation. Do not discontinue or reduce benzodiazepines independently in preparation for ketamine — any changes to your benzodiazepine regimen should happen under medical supervision.
How quickly might I notice anxiety relief from ketamine infusions? Some patients notice a reduction in anxiety symptoms during or shortly after the first infusion. Others see changes build across sessions. The timeline varies by individual, and we do not guarantee a specific onset window. What is consistent in the clinical literature is that ketamine’s action is faster than conventional antidepressants and anxiolytics — often hours rather than weeks.
Does ketamine treat panic disorder specifically? IV ketamine therapy for anxiety at our clinic addresses generalized anxiety, social anxiety, and panic disorder. The glutamate mechanism relevant to anxiety broadly applies to panic presentations, as NMDA overactivity and hyperexcitable neural states are implicated across anxiety subtypes. Your intake evaluation will determine whether your specific presentation is a good fit for our protocol.
Will I still need therapy if I pursue ketamine for anxiety? Ketamine addresses the neurobiological substrate of anxiety. Therapy addresses the cognitive, behavioral, and relational dimensions. For many patients, both are relevant, and the neuroplastic window that ketamine may open can make therapeutic work more accessible. Whether therapy is part of your plan is a question to explore with your provider based on your history and goals.
What distinguishes ketamine from the SSRIs I have already tried? SSRIs primarily target the serotonin system and require weeks to produce their full effect. Ketamine acts on the glutamate system via NMDA receptors, produces effects within hours, and promotes neuroplasticity in ways that serotonergic medications do not. If your anxiety has not responded to SSRIs or SNRIs, that history tells us about those mechanisms — it does not predict your response to a treatment that operates through an entirely different pathway. You can review common ketamine therapy FAQs to learn more before your first appointment.
Key Takeaways
- Benzodiazepines manage acute anxiety symptoms through GABA enhancement but are associated with dependence, cognitive effects, and rebound anxiety with long-term use — and do not address the glutamate dysregulation involved in treatment-resistant anxiety.
- IV ketamine targets NMDA receptors in the glutamate system, a distinct pathway not addressed by benzodiazepines, SSRIs, or SNRIs, and promotes neuroplasticity that may alter the neural architecture sustaining chronic anxiety.
- Clinical evidence supports ketamine’s rapid and significant reduction of anxiety symptoms in patients who have not responded to conventional treatments.
- At Scottsdale Ketamine Clinic, IV ketamine therapy is available for generalized anxiety disorder, social anxiety, and panic disorder following a thorough intake evaluation.
- Patients currently using benzodiazepines should not discontinue them independently; transitioning is a supervised clinical process, and ketamine’s role within that process is evaluated individually.
Anxiety that has not responded to the standard treatments is not untreatable — it may simply require a treatment that addresses the neural mechanisms the standard options were never designed to reach. Results vary by individual, and we make no guarantees about outcomes. What we do offer is a clinical evaluation that takes your full history seriously and gives you a direct answer about whether IV ketamine therapy is a reasonable next step. Call our Scottsdale clinic at 480-613-3226 or our Phoenix location at 480-590-6154 to schedule a free consultation.
References
National Center for Biotechnology Information. Dangers of Benzodiazepines. https://pmc.ncbi.nlm.nih.gov/articles/PMC8629021/
National Center for Biotechnology Information. Ketamine for Anxiety. https://pubmed.ncbi.nlm.nih.gov/31339086/
National Center for Biotechnology Information. Ketamine and Neuroplasticity. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/
American Journal of Psychiatry. Link Between Anxiety and Depression. https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.20030305
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. IV ketamine infusion therapy for anxiety should only be pursued under the supervision of a licensed medical provider familiar with your complete medical and psychiatric history. Individual results vary. Not all patients are candidates for ketamine therapy. Do not discontinue or reduce benzodiazepines or other medications without medical supervision. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
